CDH1 and prostate cancer: RANKL-activation of RANK increased expression of vimentin, N-cadherin, Snail, and Twist, decreased the expression of E-cadherin and drove EMT in normal breast acinar cells and a number of cancers including breast cancer [127], hepatocellular carcinoma [128, 129], endometrial [130, 131], lung [132] and prostate cancer [126].